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reveals an uncoupling from plasma cell differentiation
Jennifer Shrimpton,1 Matthew A. Care,1 Jonathan Carmichael,1 Kieran Walker,1 Paul Evans,2 Charlotte Evans,1,2 Ruth de Tute,2
Roger Owen,2 Reuben M. Tooze,1,2 and Gina M. Doody1
1Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; and 2Haematological Malignancy Diagnostic
Service, St James’s Institute of Oncology, Leeds, United Kingdom
Key Points
• TLR signals in WM
B cells fail to drive
plasma cell differentia-
tion while CD40L-
mediated differentiation
is intact.
• Functional TLR uncou-
pling provides an ex-
planation for the
balance between B-cell
and plasma cell disease
components.
Waldenstro¨m macroglobulinemia (WM) is a rare malignancy in which clonal B cells
infiltrate the bonemarrow and give rise to a smaller compartment of neoplastic plasma cells
that secrete monoclonal immunoglobulin M paraprotein. Recent studies into underlying
mutations in WM have enabled a much greater insight into the pathogenesis of this
lymphoma. However, there is considerably less characterization of the way in which WM
B cells differentiate and how they respond to immune stimuli. In this study, we assess WM
B-cell differentiation using an established in vitro model system. Using T-cell–dependent
conditions, we obtained CD1381 plasma cells fromWM samples with a frequency similar to
experiments performed with B cells from normal donors. Unexpectedly, a proportion of the
WM B cells failed to upregulate CD38, a surface marker that is normally associated with
plasmablast transition and maintained as the cells proceed with differentiation. In normal
B cells, concomitant Toll-like receptor 7 (TLR7) activation and B-cell receptor cross-linking
drives proliferation, followed by differentiation at similar efficiency to CD40-mediated
stimulation. In contrast, we found that, upon stimulation with TLR7 agonist R848,WMB cells
failed to execute the appropriate changes in transcriptional regulators, identifying an
uncoupling of TLR signaling from the plasma cell differentiation program. Provision of
CD40L was sufficient to overcome this defect. Thus, the limited clonotypic WM plasma cell
differentiation observed in vivo may result from a strict requirement for integrated
activation.
Introduction
Dysregulation of B-cell signaling can result in a multitude of lymphoproliferative diseases that can affect
each stage of differentiation. Waldenstro¨m macroglobulinemia (WM) is a rare lymphoplasmacytic
lymphoma that is characterized by the infiltration and accumulation of clonal B lymphocytes in the bone
marrow that give rise to a small number of neoplastic plasma cells (PCs) that are likely to be the main
source of secreted immunoglobulin M (IgM) paraprotein.1-3 WM represents a challenging neoplasm to
model in vitro because the B-cell and PC compartments are affected. An understanding of both is
required to inform potential treatments, because current regimens only target the B-cell stage.
Investigation into the pathogenesis of WM identified the recurrent somatic MYD88L265P as the most
prevalent mutation in WM, present in .90% of patients.4 MYD88 is an adaptor protein for all Toll-like
receptors (TLRs), with the exception of TLR3.5 Ligation of TLRs induces receptor dimerization,
facilitating MYD88 recruitment. Subsequently, MYD88 undergoes oligomerization and forms a complex
Submitted 25 November 2019; accepted 8 May 2020; published online 23 June 2020.
DOI 10.1182/bloodadvances.2019001279.
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with the serine/threonine kinases IRAK4 and IRAK1. Activation of
this pathway results in the nuclear translocation of nuclear factor-kB
(NF-kB) and gene expression linked to cell survival.6,7
A key part of this signaling cascade is the formation of the
myddosome complex.8,9 The L265P mutation increases the
propensity of MYD88 to form spontaneous myddosomes without
the requirement of TLR signaling.8,10 However, murine B cells that
acutely express MYD88L265P require the presence of TLR9 to
trigger spontaneous proliferation,11 and human ABC-DLBCL lines
harboring combined MYD88L265P/CD79B mutations are also
dependent on TLR9.12 Thus, whether MYD88L265P can function
independently of the upstream context remains an open question.
Here, we report the first detailed investigation of the differentiation
of primary WM B cells in vitro. We examine the response of WM
cells expressing MYD88L265P to multiple stimuli that generate PCs,
including TLR engagement, and uncover an unanticipated effect on
differentiation.
Methods
Clinical samples
Peripheral blood was obtained from healthy donors with
informed consent. Patient bone marrow aspirates and peripheral
blood from 14 WM patients, 6 splenic marginal zone lymphoma
(SMZL) patients, 1 chronic lymphocytic leukemia patient, and 1
mantle cell lymphoma patient fulfilling World Health Organiza-
tion diagnostic criteria were included in this analysis. CXCR4
mutations were confirmed by Sanger sequencing. All of the
samples were obtained at initial presentation. Approval for the
study was granted by the Leeds (East) NHS Research Ethics
Committee.
In vitro generation of PCs
B cells were isolated by negative selection with a Memory B Cell
Isolation Kit (Miltenyi Biotec) or were positively selected with
CD20 MicroBeads and cultured in Iscove modified Dulbecco
medium 1 10% fetal bovine serum (Invitrogen) with the addition
of human interleukin-2 (20 U/mL), human interleukin-21 (50 ng/mL),
and F(ab9)2 goat anti-human IgM and IgG (10 mg/mL). B cells
were stimulated with the TLR7/8 agonist R848 (InvivoGen) or
g-irradiated CD40L-expressing L cells (supplemental Figure 1).
Subsequent culture followed the protocol detailed by Cocco et al.13
Cells were quantified by flow cytometry using CountBright Beads
(Thermo Fisher Scientific).
Flow cytometry
The antibodies used for cell surface staining included CD20 (130-
091-104), CD27-FITC (M-T271) (BD Biosciences), CD19-PE
(LT19; Miltenyi Biotec), CD20-Pacific Blue (2H7; eBioscience),
CD38-APC-Cy7 (HB-7; BD Biosciences), CD138-APC (44F9;
Miltenyi Biotec), and 7-AAD-PerCP-Cy5 (BD Biosciences). Flow
cytometry was performed using a BD LSR II 3 Laser (BD
Biosciences) or a CytoFLEX S (Beckman Coulter). Analysis was
performed using FACSDiva Software v8.0.0 (BD Biosciences) or
FlowJo v10 (TreeStar).
SPADE analysis
viSNE (Visualization of t-distributed Stochastic Neighbor Embedding)
maps were generated using proportional sampling of concatenated
data in Cytobank (https://www.cytobank.org). Analysis was per-
formed using the default t-distributed Stochastic Neighbor Embed-
ding parameters but with perplexity 5 50 and 5000 iterations.
Clustering analysis was performed with SPADE (Spanning-tree
Progression Analysis of Density-normalized Events) using default
analysis parameters. Clusters of nodes were labeled manually
according to the phenotype.
RNA sequencing
Sequencing libraries were generated using a TruSeq Stranded
Total RNA Library Prep Human/Mouse/Rat kit and sequenced on
a NextSeq 500 System (both from Illumina) using 76-bp single-end
sequencing. The fastq files were trimmed using TrimGalore v0.6.0
and aligned to GRCh38.p12 (GENCODE, release 28) with STAR
aligner (v2.6.0c).14 Transcript abundance was estimated using
RSEM v1.3.0 and processed using DESeq2 v1.22.2.15-18 Signifi-
cantly differentially expressed genes (1.4 fold-change, false discovery
rate ,0.05) were analyzed by the Database for Annotation,
Visualization and Integrated Discovery functional annotation tool
(Laboratory of Human Retrovirology and Immunoinformatics). RNA-
sequencing (RNA-seq) data were aligned to the immunoglobulin
heavy chain reference library using MIXCR v3.0.9,19 and clones
were defined by the presence of a unique CDR3 sequence.
Resulting output was analyzed using R version 3.5.1 and visualized
using ggplot2.20
Results
In vitro differentiation of WM B cells
The response of B cells can generally be divided into 2 categories:
those that require T-cell help (T-dependent [TD] responses) and
those that do not (T-independent [TI] responses). Therefore, we
initially sought to characterize the response of WM B cells to TD
stimuli because the response of healthy cells in this system has
already been established.
In our model, WM total B cells were stimulated in a manner that
mimics TD activation by coculture with CD40L-expressing fibro-
blasts and cross-linking the B-cell receptor (BCR) with F(ab9)2 anti-
IgG/IgM. Throughout the culture, the immunophenotype of the cells
was determined at time points corresponding to the different
recognized stages of B-cell differentiation. Under these conditions,
WM cells had acquired a plasmablast-like phenotype by day 6,
having downregulated the expression of CD20 and upregulated the
plasmablast marker CD38 (Figure 1A). Examination of RNA-seq
confirmed the clonal nature of the cells generated from WM
samples (Figure 1B), as well as the presence of the MYD88L265P
mutation (Figure 1C).
We successfully produced a population of WM PCs by day 13, at
which time a high proportion of cells had acquired CD38 and
CD138. These were mature PCs; once generated, they could be
maintained until elective termination. The pattern of cell surface
marker expression changes was largely consistent between
samples from different patients and were not impacted by CXCR4
mutation status, although there was a trend toward a lower
percentage of CD38 expressing cells in WM samples with mutated
CXCR4 (Figure 1D-F).
Although differentiation occurred in a similar manner in healthy and
WM B cells, there was a greater degree of heterogeneity among
patient samples. Most WM B cells stimulated in a TD manner
2822 SHRIMPTON et al 23 JUNE 2020 x VOLUME 4, NUMBER 12
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
s
h
p
u
b
lic
a
tio
n
s
.o
rg
/b
lo
o
d
a
d
v
a
n
c
e
s
/a
rtic
le
-p
d
f/4
/1
2
/2
8
2
1
/1
7
4
5
7
8
7
/a
d
v
a
n
c
e
s
a
d
v
2
0
1
9
0
0
1
2
7
9
.p
d
f b
y
 g
u
e
s
t o
n
 1
7
 J
u
ly
 2
0
2
0
100%
75%
50%
25%
WM4 WM5 WM6 WM7
100%
%
 c
lo
na
l c
om
po
si
tio
n 
of
 B
CR
 r
ep
er
to
ire
75%
50%
25%
Donor 2 Donor 3 Donor 6
A B
G
G
T G C C C A T C A G A A G C G A C T G A T C C C C A T C A A G T A C A A G
T G C C C A T C A G A A G C G A C C G A T C C C C A T C A A G T A C A A G
Healthy
Sequence
WM
Sequence
C
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
 +
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
 +
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
 +
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
 +
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
 +
E
Time point (days)
Po
si
tiv
e 
ce
lls
 (
%
)
CD19 CD20
WM
CD27 CD38 CD138
WM1
WM2
WM3
WM4
WM5
WM6
WM6
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
+
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
+
70
+
CD20
D
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
 +
70
 +
Po
si
tiv
e 
ce
lls
 (
%
)
Time point (days)
CD19
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
+
70
+
Healthy
CD27
100
80
60
40
20
0
0 6
13
-1
5
20
-2
2
28
-3
2
40
+
70
+
CD38 CD138
D1
D2
D3
D4
D5
D6
D7
D8
D9
D10
D11
D12
107
106
105
104
0
-104
0 104 105 106 107
107
106
105
104
103
0
-103
0 104 105 106 107
107
106
105
104
0
0 104 105 106 107
107
106
105
104
0
-104
0 104 105 106 107
0 104 105 106 107 0 104 105 106 107 0 104 105 106 107 0 104 105 106 107
0 104 105 106 107 0 104 105 106 107 0 104 105 106 107 0 104 105 106 107
0 104 105 106 107 0 104 105 106 107 0 104 105 106 107 0 104 105 106 107
0 104 105 106 107 0 104 105 106 107 104 105 106 107 0 104 105 106 107
107
106
105
104
0
107
106
105
104
0
-104
107
106
105
104
103
102
103102
107
106
105
104
103
0
-104
107
106
105
104
0
107
106
105
104
0
-104
107
106
105
104
0
107
106
105
104
0
107
106
105
104
0
-104
107
106
105
104
103
0
-103
107
106
105
104
0
-104
107
106
105
104
103
0
-103
107
106
105
104
0
-104
107
106
105
104
103
0
-103
107
106
105
104
0
-104
107
106
105
104
103
0
CD
19
CD20
CD
38
CD
19
CD
38
CD138 CD20 CD138
Day 0
Healthy WM
Day 6
Day 13
Day 22
Day 32
Figure 1. WM B cells generate PCs in vitro following culture with TD stimuli. (A) Representative flow cytometric plots depicting phenotypic characterization of
differentiating B cells derived from the peripheral blood of healthy donors (left panels) or WM patients (right panels) stimulated with CD40L and F(ab9)2 anti-IgG/IgM. The day
of culture is indicated on the left. (B) The proportion of the IgH repertoire occupied by each clone was plotted for healthy donor (upper panel) or WM (lower panel) samples
stimulated with CD40L and F(ab9)2 anti-IgG/IgM, with each unique clone represented by a colored band. The top 250 clones are shown. (C) Reads from RNA-seq from
representative day-6 samples taken from healthy donors and WM differentiations, highlighting the L265P somatic variant (T.C). (D) Phenotypic profiles for B cells derived from
the peripheral blood of healthy donors (D1-D12). Each scatter plot displays the percentage of live cells expressing the stated CD marker, as determined at each time point via
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acquired surface markers that were characteristic of PCs by day
13; however, it appears that a proportion of the cells go through an
alternate plasmablast-like phenotype (Figure 1G). These cells
express CD138 but do so without prior upregulation of CD38,
the characteristic plasmablast marker. This population was
observed to persist for several weeks.
Once B cells have become activated, they proliferate rapidly and
give rise to effector cells. At the end of this response, many of these
cells die, but a small number of long-lived PCs persist. The in vitro
system replicates these dynamics for healthy and WM cells. The
expansion in the number of B cells derived from healthy donors can
be as much as 40-fold, whereas the increase in WM cells is less
profound (Figure 1H). There is also a reduction in the overall output
of PCs normalized to the input cell number compared with healthy
cells (day 21: healthy, 1.386 2.03 vsWM, 0.246 0.2; day 28: 1.18
6 1.42 vs 0.21 6 0.18, respectively). Despite differences in
the amplitude, WM cells exhibit a similar response to that of
healthy cells.
A TLR7 agonist inhibits the proliferation and survival
of WM B cells
The above results confirm that WM B cells can successfully
generate PCs using an in vitro system that mimics the response to
a TD antigen. In this scenario, the presence of the MYD88L265P
mutation appears to have minimal influence on the production of
antibody-secreting cells. However, PCs are also generated in the
context of TI responses, involving receipt of costimulatory signals
from other sources, including TLR activation by pathogen-
associated molecular patterns (PAMPs).21
TLR stimulation induces a signaling cascade through MYD88,
which ultimately results in the translocation of NF-kB to the nucleus
and expression of genes required for survival and proliferation.
Previous studies have suggested that B cells harboring the
MYD88L265P mutation require continued TLR activity to maintain
proliferation,11,12,22 but it remains unknown whether WM cells
behave differently when exposed to PAMPs that drive PC
production.
Therefore, we investigated whether activating WM B cells in a TI
manner, through ligation of TLR7 with its synthetic ligand R848,
would enhance the proliferation or survival of these cells. Initial
experiments performed on healthy donors determined that,
although stimulation of B cells with R848 alone was sufficient to
promote PC differentiation, the process lagged behind the TD
version and resulted in a persistent B-cell population (supple-
mental Figure 1). In some instances, exposure to antigen and
PAMPs occurs simultaneously, which can enhance antibody
responses.23,24 Therefore, healthy control cells were also
stimulated with R848 combined with F(ab9)2 anti-IgG/IgM. Cells
treated with this combination exhibited a profile that was similar to
the TD conditions (Figure 2A-B). Unexpectedly, stimulation of
WM cells with R8481anti-BCR led to an abrupt decline in cell
numbers, resulting in virtually no viable cells by day 14, regardless
of CXCR4 mutation status (Figure 2B). This is in contrast to the
response shown by healthy cells to R848. Furthermore, WM cells
do not follow the usual pattern of phenotypic differentiation when
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WM4                  p.S338X C>G
WM7                  p.S338Ffs*6  insT
WM8                  p.H337fs*2 del20
F
G
CD138
CD
38
Healthy
105
104
103
0
-103
0 103 104 105
WM
105
104
103
102
0
-102
0 103 104 105
107
106
105
104
0
-104
0-104 104 105
107
106
105
104
0
0 104 105 106 107
107
106
105
104
0
0 104 105 106 107
105
104
103
0
-103
0 103-103 104 105
107
106
105
104
103
0
0 104 105-104 106 107
H
Fo
ld
 c
ha
ng
e
Day 
WM 3
WM 4
WM 5
WM 6
WM 7
WM 8
D 1
D 2
D 3
D 4
D 5
D 6
D 7
D 8
D 9
D 10
D 11
D 12
D13
50
40
30
20
10
0
0 5 10 15 20 25 30
8
6
4
2
0
0 5 10 15 20 25 30
Figure 1. (continued) flow cytometry Data from comparable intervals were grouped together for clarity. Each independent differentiation is represented by a different
color. (E) Phenotypic profiles for B cells derived from the bone marrow of WM patients stimulated with CD40L and F(ab9)2 anti-IgG/IgM. Each independent
differentiation is represented by a different color, and samples with CXCR4 mutations are shown in red (WM4 and WM7). (F) CXCR4 mutations detected among WM
samples. (G) Representative plots of CD38 and CD138 expression on day-13 cells from 1 healthy donor and 6 WM samples. (H) The fold change in cell number from
healthy donors (upper panel) and WM samples (lower panel) at each time point was determined by manual counts between day 0 and day 6 and by flow cytometry
thereafter. The cell number at each point was normalized to the number of “input” cells for that specific donor obtained at day 0. Samples with CXCR4 mutations are
indicated by red font.
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Figure 2. WM B cells fail to differentiate in response to the TLR7 agonist R848. (A) B cells derived from the peripheral blood of healthy donors were stimulated with 1
mg/mL R848 and F(ab9)2 anti-IgG/IgM. Each scatter plot displays the percentage of live cells expressing the stated CD marker, as determined at each time point via flow
cytometry. Data from comparable intervals were grouped together for clarity. Each independent differentiation is represented by a different color. (B) The fold change in cell
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stimulated with R848. A large proportion of cells retain a less
mature phenotype (Figure 2C), whereas in healthy controls,
activation with R848 promotes the acquisition of CD138 as
efficiently as CD40L.
Previous studies have demonstrated that interactions among TLRs,
CD40L, and the BCR affect the ability of B cells to class switch and
undergo differentiation.25,26 Therefore, the effect of combining
CD40L and R848 stimulation was assessed. B cells from 2 donors
were stimulated concurrently with CD40L1anti-BCR (CD40L),
R8481anti-BCR (R848), or a combination of CD40L and
R8481anti-BCR (CD40L1R848). B cells proliferated better
following stimulation with CD40L compared with R848 (Figure 3A),
and cells that received CD40L1R848 proliferated to a similar extent
as their counterparts that received CD40L stimulation. The difference
in cell number between CD40L alone and CD40L1R848 was
minimal.
The response of WM B cells was then examined to investi-
gate whether the failure to proliferate and differentiate following
R848 stimulation could be ameliorated by costimulation with
CD40L1R848.
Between days 0 and 3, cell numbers were maintained within
cultures that received CD40L stimuli, but cells that were stimulated
with R848 alone had decreased considerably in number
(Figure 3A). The decline continued for the R848-stimulated cells
until there were very few cells left from day 13 onward. In contrast,
cells under CD40L-stimulated conditions proliferated between days
3 and 6; WM cells stimulated with a combination of CD40L1R848
proliferated to a greater extent than did those that received only
CD40L. The numbers of cells from the CD40L1R848-stimulated
condition remained higher than those stimulated with CD40L alone
until day 20 of the differentiation, after which the 2 conditions had
very similar numbers of cells.
The phenotype of the cells in each condition is displayed in Figure
3B-C. At day 6, the phenotype of the dual-stimulated cells was
virtually indistinguishable from those that received CD40L. The cells
stimulated with CD40L1R848 continued to have almost the same
phenotype as the CD40L-only group throughout the rest of the
differentiation. In contrast, the R848-stimulated WM cells failed to
differentiate.
Differentiation profiles from non-WM LPDs
To determine whether the features of in vitro WM differentiation
were unique, we investigated the profile of B cells from other
lymphoproliferative disorders (LPDs), notably SMZL cells. The
capacity to differentiate into PCs appears to be conserved in
a proportion of SMZL cases (21-74%).27-30 Similar to WM,
dysregulation of NF-kB signaling also plays a key role in SMZL
pathogenesis,31-33 although the frequency of MYD88L265P muta-
tion is low.34-36
B cells were isolated and stimulated as described previously. A
summary of the input samples is provided, accompanied by the
capacity of B cells from each sample to generate plasmablasts or
PCs in vitro (supplemental Table 1). All samples were negative for
the MYD88L265P mutation, as determined by allele-specific
oligonucleotide polymerase chain reaction.
The expression of each marker, with the exception of CD19, was
highly variable between the samples, as was the extent to which
they were able to differentiate when stimulated with CD40L1anti-
BCR (Figure 4A). Like WM, these cells also responded poorly to
a TI stimulus. Only 1 of the samples (patient 6) was able to
generate PCs (Figure 4B). This is in contrast to the phenotypes
obtained when the cells were stimulated with CD40L: all but 1
sample exhibited some ability to generate PCs. No evidence of
a CD382CD1381 population akin to that of the WM samples was
observed, indicating that the phenotype may be restricted to
WM cells.
LPD samples, with the exception of patient 1, displayed a weaker
proliferative response to stimulation with R8481anti-BCR in
comparison with that observed following CD40L1anti-BCR
(Figure 4C). In addition, samples capable of generating PCs
following activation with CD40L were, in general, less able to do so
subsequent to TLR7 stimulation. The variable capacity for PC
differentiation among these samples in vitro is in line with the
spectrum of differentiation observed in vivo. Despite the fact that
the profiles initially appeared similar between WM and the other
LPDs, direct comparison of the proliferation of these samples
reveals that the divergent response of WM B cells to these stimuli is
more extreme.
Determination of cellular hierarchy using SPADE
viSNE was used to identify populations that become apparent when
multiple data sets are analyzed simultaneously and explore differ-
ences among differentiations with WM-derived cells, LPD cells,
and healthy cells. The relationships between the populations of
cells generated in each group were examined using SPADE plots
generated from the initial viSNE results.
Figure 5A depicts SPADE plots constructed from WM concate-
nated flow data at day 13 of differentiation, with the intensity of
expression of CD38 and CD138 indicated. The equivalent plots of
concatenated healthy cells at this time point are shown on the left
for comparison. In the upper healthy SPADE tree, all nodes are
orange or red, denoting high levels of CD38 in all cells; the lower
tree illustrates the separation of plasmablasts and PCs by CD138
expression. However, in the CD38 WM tree, a distinct collection of
green nodes can be seen. TheseCD38-low cells have a comparable
level of CD138 expression as the WM cells that fall within the
“classic” PC group and, thus, are the atypical CD382CD1381
fraction. The most closely related healthy cells lie further up the
branch located within the plasmablast group, suggesting that the
CD382CD1381 cells are more similar to healthy plasmablasts than
to PCs.
Figure 2. (continued) number from healthy donors (left panel) and WM samples (right panel) at each time point was determined by manual counts between day 0 and day
6 and by flow cytometry thereafter. The cell number at each point was normalized to the number of “input” cells for that specific donor obtained at day 0. WM samples with
CXCR4 mutations are shown in red (WM7 and WM8). (C) B cells derived from the bone marrow of patients diagnosed with WM were stimulated with 1 mg/mL R848 and
F(ab9)2 anti-IgG/IgM and profiled for markers as in panel A.
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The similarity in the phenotypes of healthy cells stimulated with
CD40L or R848 is demonstrated in supplemental Figure 2.
However, SPADE highlights the fact that the greatest divergence
between samples occurs at day 6 of the differentiation. Although
differences are observed in the healthy group at day 6 of the
differentiation, the final results following either stimulation are
almost identical from day 13 onward. The responses of all of the
LPD samples to the 2 types of stimulation at day 13 of the
differentiation in comparison with healthy cells are summarized in
Figure 5B. The overlap between the healthy cells with either
stimulation is extensive, in contrast to the LPDs. The profound
inability of WM cells to respond correctly to TLR7 stimulation
predominates in the R848 plots, with the LPD plasmablasts
generated earlier in the time course unable to survive to this
time point.
R848-stimulated WM cells fail to mount an effective
PC gene expression program
To provide insight into the distinct WM responses to PC-inducing
stimuli, RNA-seq was performed on material harvested from cells
at day 6 of culture within the in vitro system, because this time point
showed the greatest degree of difference in the SPADE analysis.
The samples consisted of 3 healthy controls with matched samples
for CD40L and R848 stimulation and a total of 6 WM samples
(Figure 6A).
The numbers of significantly up- or downregulated genes
between healthy and WM samples and between the different
activation stimuli are displayed in Figure 6B. The greatest
difference in gene expression occurs between WM and healthy
samples, with WM samples demonstrating a considerably
greater proportion of upregulated genes. As might be antic-
ipated from the characterization of the differentiation responses,
the number of differentially expressed genes between WM and
healthy cells following CD40L stimulation is smaller than that for
R848 stimulation.
One of the most important questions to address was whether
WM cells are able to successfully integrate TLR7 signals to
initiate B-cell activation, because a failure to do so could explain
the profound loss of cell number. The sequencing data reveal
that, in fact, TLR7 messenger RNA is the most highly expressed
endosomal TLR in healthy and WM samples (supplemental
Figure 3). The expression of TLR7 messenger RNA was similar
between healthy and WM cells, with WM cells expressing
slightly lower levels. Moreover, the results indicate that TLR7
stimulation does indeed activate WM B cells. Stimulation of WM
cells with R848 upregulates multiple genes associated with
B-cell activation that are similarly upregulated in R848-
stimulated healthy cells, including FOSB, JUND, IL2RA, and
SDC1 (supplemental Figure 3). Having established that WM
cells remain capable of being activated by TLR7 ligation, the
failure of these cells to successfully differentiate/survive may
be due to a perturbation of the genes associated with PC
differentiation.
Indeed, WM cells demonstrated differential expression of multiple
key genes within the PC-differentiation pathway compared with
healthy cells. Differences in gene expression were apparent
subsequent to both types of stimulation (Figure 6C). For WM cells
stimulated with CD40L, fewer genes were significantly differen-
tially expressed compared with WM samples activated with R848.
WM cells exhibited decreased levels of PRDM1 (encoding the
master regulator of PC differentiation BLIMP1), TNFRSF17
(encoding BCMA, which is important for PC survival), and
POU2AF1; conversely, increased levels of BACH2, STAT3, and
SPIB, which are associated with the B-cell program, were
observed.37,38 This pattern supports previous phenotypic analysis
and may explain the delay in differentiation that is sometimes
observed in WM cells in comparison with their healthy
counterparts.
A greater number of members of this pathway are perturbed in WM
cells subsequent to R848 stimulation. IRF8, BACH2, SPIB, and
MITF exhibit significantly increased expression, associated with
repression of IRF4 and PRDM1, and indicative of an impediment to
PC differentiation. The elevated levels of BACH2, SPIB, and IRF8
suggest that WM cells respond to activation but are then unable to
progress beyond the preplasmablast state.
To highlight additional pathways that would be affected by the
altered expression levels between the different samples and
conditions, comparisons of differentially expressed genes were
performed between and within the healthy and WM groups and
subsequently analyzed using the Database for Annotation,
Visualization and Integrated Discovery functional annotation
tool. Components of 3 major pathways were upregulated among
the WM samples compared with the healthy controls (Table 1).
As expected, the NF-kB pathway was highlighted by the
functional annotation tool. Cytokine signaling plays a key role
in WM pathogenesis; mutations in CXCR4 are the most
common after MYD88 and are central to the homing of WM
cells to the bone marrow.39-41 Therefore, it is not surprising for
components of these pathways to be upregulated. In particular,
the chemokines CCR4, CCR7, and CCL5, as well as CXCR4
and multiple members of the tumor necrosis factor (TNF) family,
are elevated in the WM samples. This is in accordance with the
findings of Ngo et al,39 and such genes are characteristic of
activated B cells.42
Many of the genes upregulated in WM cells compared with healthy
cells following CD40L stimulation are consistent with previously
documented WM transcriptomic analyses.43-45 Because the WM
samples used for CD40L stimulations consisted of an equal number
of wild-type and mutated CXCR4, the number of differentially
expressed genes between the 2 groups was also evaluated. A total
of 159 genes showed significant changes, and only 11 of which
Figure 3. Combinatorial activation of WM B cells by TLR7 agonist, BCR triggering, and T-cell help generates PCs. (A) B cells derived from the peripheral blood of
2 healthy donors (left panel) or 2 WM patients (middle and right panels) were stimulated with CD40L1anti-BCR (CD40L), CD40L1R8481anti-BCR (CD40L1R848), or
R8481anti-BCR (R848). The fold change in cell number at each time point was determined by manual counts for day 3 and day 6 and then by flow cytometry thereafter. The
cell number at each point was normalized to the number of “input” cells for that specific patient obtained at day 0. The immunophenotype of cells from a representative healthy
(B) or WM (C) sample, stimulated as in panel A, was assayed by flow cytometry at each time point. Percentages are displayed for each quadrant.
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were upregulated in the CXCR4 mutated samples (supplemental
Figure 4). In contrast to the results reported by Hunter et al,45 there
did not appear to be any bias toward enhanced differentiation in the
CXCR4 wild-type samples or a clear impact on TLR or MAPK
signaling associated with CXCR4 mutations. The lack of concor-
dance between the 2 sets of results may be largely dictated by the
Figure 4. B cells from other LPDs display variable PC differentiation in vitro. B cells derived from the bone marrow (BM), peripheral blood (PB), or spleen of patients
with various LPDs were stimulated with CD40L and F(ab9)2 anti-IgG/IgM (A) or 1 mg/mL R848 and F(ab9)2 anti-IgG/IgM (B). Each scatter plot displays the percentage of live
cells expressing the stated CD marker, as determined at each time point via flow cytometry. Data from comparable intervals were grouped together. Each independent
differentiation is represented by a different color. (C) The fold change in cell number at each time point was determined by manual counts for day 3 and day 6 and by flow
cytometry thereafter. The cell number at each point was normalized to the number of “input” cells for that specific patient obtained at day 0.
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Figure 5. SPADE plots depicting population
relationships during in vitro differentiation. (A)
Plots showing related phenotypes in healthy and
WM samples based on CD38 and CD138 expres-
sion among day-13 cells that had been stimulated
with CD40L and F(ab9)2 anti-IgG/IgM at day 0. Each
node is colored according to the median intensity of
the indicated marker and is proportional in size to
the number of cells with that marker intensity. (B)
Visualization of the branched interconnectivity of
healthy day-13 cells vs all LPDs, including WM, in
response to CD40L or R848 stimulation based on
CD38 or CD138 expression.
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differentiation stage from which the material was obtained.
However, GRN and LGALS3BP are among the shared genes that
showed reduced levels in mutated CXCR4 samples; they exhibit
similar patterns of expression during differentiation, with highest
levels in mature PCs (supplemental Figure 4C). Both genes encode
secreted proteins with a range of properties,46,47 and progranulin, in
particular, has been linked to multiple myeloma cell survival and
treatment resistance.48,49
As with the comparison of cells stimulated with CD40L, WM
cells stimulated with R848 demonstrate elevated expression
levels of genes associated with TLR and NF-kB signaling. Once
again, WM cells demonstrate upregulation of numerous
components involved in cell-cell interaction, but to an even
greater extent than following CD40L stimulation. This suggests
that the R848-stimulated WM cells are trapped at the activated
B-cell state.
Discussion
WM is a heterogenous disease comprising malignant B cells and
their more differentiated progeny. This study represents the first
time that the differentiation of primary human WM B cells has been
investigated, in an in vitro setting, in response to TD and TI stimuli.
WM cells successfully generated PCs that were phenotypi-
cally identical to those from healthy individuals when provided with
stimuli that mimics TD activation. However, in contrast to healthy
individuals, approximately half of the WM samples also generated
a novel population of CD382 PCs that have not been described
previously. The relationship between these cells and the other
phenotypic fractions generated by the SPADE algorithm suggests
that these cells are more similar to plasmablasts on the cusp of
becoming PCs than to traditional CD381CD1382 plasmablasts.
Therefore, differentiation of WM cells may occur in a manner
analogous to that of the model proposed by Avery and
colleagues, in which memory cells generate CD382 and
CD381 plasmablast fractions subsequent to activation.50 The
distinct nature of these cells may also reflect the aberrant gene
expression pattern in purified ex vivo WM PCs, which appear to
express a profile consistent with an intermediate stage
between B cells and PCs.51 This fraction and the conventional
CD381CD1381 PCs generated by WM cells demonstrate an
equivalent lifespan to those generated by healthy controls and
represent a truly long-lived PC population, persisting in culture
in excess of 40 days.
Research undertaken by 2 groups of investigators suggested that
MYD88L265P-expressing cells still require TLR signals for pro-
liferation and their continued survival.11,12 Therefore, the effect of
TLR7 stimulation on WM cells was assessed to determine whether
this translated into enhanced differentiation. In contrast to the
expectation of improved survival, WM cells exhibited a profoundly
deleterious response to R848.
RNA-seq established that WM cells are able to be activated by
a combination of TLR7 and BCR signaling, yet the majority of
these cells are unable to generate a PC population. This implies
that there is a failure of downstream signaling to integrate the
activation signal with the PC-differentiation pathway. Multiple
essential regulators of PC differentiation appear to be dysregu-
lated in WM cells stimulated with the TLR7 agonist. Central to
differentiation is PRDM1, encoding BLIMP-1, termed the master
regulator of PC differentiation because of its essential nature for
this process. RNA-seq data confirmed that IRF4 and PRDM1
were significantly downregulated in WM cells stimulated with
R848, whereas suppressors of these transcription factors, such
as SPIB, BACH2, andMITF, were significantly upregulated. This
provides a molecular explanation for the failure of R848-
stimulated WM cells to generate PCs, despite retaining the
capacity to do so following CD40L stimulation. Further testing
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Figure 5. (Continued).
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using B cells from MYD88WT WM cases will help to confirm
whether these effects are strictly related to the presence of the
mutated form of MYD88.
It is possible that the chronic intrinsic activation of the TLR pathway
via MYD88L265P in WM cells is inducing a state of TLR tolerance,
rendering them unable to fully respond to TLR engagement and
progress further down the differentiation pathway once they have
been activated. However, because the cells are also in receipt of
a concomitant BCR signal, this should be sufficient to overcome
a refractory state.52 The further addition of CD40L to TLR7 and
BCR signaling rescued the cells from an apoptotic fate and enabled
A
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vs CD40L
WM only
R848 vs
CD40L  
1472 152453836650489 55693
C
CD40L
R848
PRDM1IRF4
MITF
IRF8
POUAF1
OCT2
STAT3
NF-mB
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Figure 6. WM cells exhibit a block in the PC gene-expression program. (A) Hierarchically clustered heat map of differentially expressed genes between healthy and
WM samples in day-6 in vitro–generated cells from R848 or CD40L conditions. The threshold for significance was a false discovery rate ,0.05. WM samples with CXCR4
mutations are indicated in red (WM4 and WM7). (B) Venn diagrams depicting the significantly differentially expressed genes for each stated comparison. The number of
upregulated genes is displayed in red, the number of downregulated genes is displayed in blue, and the number of nonsignificant genes is shown in the center. (C) The
interaction between key genes involved in PC differentiation is depicted for cells stimulated with CD40L (upper panel) or R848 (lower panel). Genes that are upregulated in
WM samples compared with healthy samples are in larger and bold type, whereas those that are downregulated are shown in smaller and italicized type.
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them to successfully undergo differentiation. This observation
suggests that the neoplastic clone requires multiple activation
signals within the local environment to drive the characteristic IgM
monoclonal gammopathy.
WM cells displayed a distinctive gene expression signature, with
functional annotation software identifying the upregulation of
numerous pathways involved in cell-cell interaction, cytokine
production, and migration, all of which are indicators of
engaging in a microenvironmental response. The bone marrow
microenvironment clearly plays a central role in WM patho-
genesis, as demonstrated by the efficacy of therapeutics
inducing egress of neoplastic cells from the bone marrow.53-56
Moreover, accumulation of excess mast cells within the bone
marrow is a characteristic feature of WM, with the presence of
these cells often aiding differential diagnoses.57,58 The
presence of mast cells has been demonstrated to promote
the proliferation of the WM clone through CD40L-CD40
interaction.59 Based on the findings presented here, it is
conceivable that the provision of CD40L by mast cells is also
required to promote the conversion of WM B cells to IgM-
secreting PCs.
In summary, the in vitro system represents a powerful tool for
studying B-cell neoplasms. It is particularly useful for investigating
WM because it enables analysis of the spectrum of B-cell
differentiation, which is impossible in cell lines. An understanding
of the bone marrow microenvironment is increasingly being
recognized as an essential component for treating WM. Currently,
a mouse model that sufficiently recapitulates this neoplasm does
not exist60; thus, the flexibility of the in vitro system will enable
superior modeling of the BM niche with patient-derived primary cells
and allow further evaluation of the WM PC compartment, including
the impact of molecular subtypes, such as CXCR4WHIM.
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